Is Sotorasib covered by medical insurance?

Sotorasib (Sotorasib) was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2021. It has not yet been launched in China, so it has not yet been included in medical insurance. Under the new approval, sotorasiib can be used to treat patients with non-small cell lung cancer (NSCLC) that has spread to nearby (locally advanced) or distant sites (metastatic) in the body. Prior to treatment with this drug, the patient had received at least one other systemic cancer treatment, such as chemotherapy, and had a specific KRAS mutation, called G12C, in his tumor.

In a preliminary and updated analysis of the Phase I/II CodeBreaK 100 trial, clinically relevant objective response rates were observed in patients with KRAS G12C mutation-positive non-small cell lung cancer. Clinically relevant durations of response were reported in an updated analysis of the trial. Sotorasiib had manageable tolerability, allowing dose adjustments to control toxicity, and participants survived an average of 13 months overall and an average of seven months without their cancer getting worse.

The Hong Kong original research versionsotorasibuSpecificationsThe price of 120mg*240 tablets is about 80,000 yuan, and the European original research version 120mg*240 tablets is priced at about 44,040 yuan (the price may fluctuate due to the exchange rate), and the price is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.